Hi there! Welcome to the first edition of 'This Week in Science', where we share exciting news and highlight the most recent scientific advances.
A breakthrough for speech-restoration devices. A groundbreaking study published in Nature Biomedical Engineering details the first successful use of a brain implant to help a bilingual individual, known as Pancho, communicate in both Spanish and English. After a stroke at age 20 left him largely paralyzed and unable to speak clearly, Pancho partnered with Edward Chang's team at the University of California, San Francisco. In 2021, they implanted electrodes on his cortex to record neural activity, which an AI system then translated into words displayed on a screen. This AI, led by PhD student Alexander Silva, was trained to recognize nearly 200 words and deciphered Pancho’s attempts to speak in either language. It used separate modules for Spanish and English, achieving an 88% accuracy in language differentiation and 75% accuracy in sentence decoding. Remarkably, the study found that both languages were processed in the same brain region, contradicting previous beliefs that different languages activate distinct brain areas. This research not only advances speech-restoration neuroprostheses but also provides insights into bilingual language processing, suggesting future applications could restore natural multilingual communication for those unable to speak.
Source: Nature
New hope to fight Alzheimer’s. Alzheimer’s disease is a progressive neurodegenerative disorder characterized by memory loss, cognitive decline, and behavioral changes, and it is the most common cause of dementia, affecting more than 55 million people worldwide. A recent clinical trial has demonstrated promising results for a new drug, LM11A-31, aimed at enhancing brain resilience in patients with mild to moderate Alzheimer's disease. Published in Nature Medicine, the trial involved 242 participants and was led by researchers from Western University, Stanford University, and UCSF. Current treatments of Alzheimer’s target amyloid beta peptides and tau protein - two proteins, the abnormal buildup of which in the brain causes Alzheimer’s. However, LM11A-31 focuses on the P75 neurotrophin receptor (P75NTR) to promote neuron survival and growth. Analysis of structural MRI, PET, and cerebrospinal fluid data indicated the drug slowed disease progression and reduced inflammation markers over a 26-week period. This study marks the first human trial targeting P75NTR and suggests potential benefits even in later stages of Alzheimer's. Further research aims to optimize treatment timing and evaluate genetic factors influencing response. If future trials confirm its efficacy, LM11A-31, which is taken orally and has minimal side effects, could significantly impact Alzheimer's treatment.
Source: Western News
Making hungry cancer cells burn out can help fight cancer. Dr. Barak Rotblat's recent study, published in Nature Communications, proposes a new method to treat brain cancer by targeting the cells' survival mechanisms during glucose starvation. Traditionally, cancer treatments focus on stopping the rapid growth of cancer cells, but Rotblat's research suggests that forcing these cells to grow quickly without enough glucose could cause them to burn out and die. The key discovery is a protein called 4EBP1 in the mTOR pathway, which helps cancer cells survive by regulating an enzyme involved in fat production. By blocking 4EBP1, the cancer cells would be unable to save energy when glucose is low, leading to their death. This method could spare healthy cells and may be useful for treating other types of cancer, offering a more targeted and less harmful alternative to current treatments like chemotherapy and radiation.
Source: News Medical Lifesciences
Cover image: A futuristic brain device reading the human brain's activity. Generated by Dall-E 3.
Stats
- Recommendations n/a n/a positive of 0 vote(s)
- Views 1786
- Comments 0